Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST study

Giampiero Favato, Gianluca Baio, Alessandro Capone, Andrea Marcellusi, Silvano Costa, Giorgia Garganese, Mauro Picardo, Mike Drummond, Bengt Jonsson, Giovanni Scambia, Peter Zweifel, Francesco S. Mennini

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: The development of human papillomavirus (HPV)-related diseases is not understood perfectly and uncertainties associated with commonly utilized probabilistic models must be considered. The study assessed the cost-effectiveness of a quadrivalent-based multicohort HPV vaccination strategy within a Bayesian framework. METHODS: A full Bayesian multicohort Markov model was used, in which all unknown quantities were associated with suitable probability distributions reflecting the state of currently available knowledge. These distributions were informed by observed data or expert opinion. The model cycle lasted 1 year, whereas the follow-up time horizon was 90 years. Precancerous cervical lesions, cervical cancers, and anogenital warts were considered as outcomes. RESULTS: The base case scenario (2 cohorts of girls aged 12 and 15 y) and other multicohort vaccination strategies (additional cohorts aged 18 and 25 y) were cost-effective, with a discounted cost per quality-adjusted life-year gained that corresponded to &OV0556;12,013, &OV0556;13,232, and &OV0556;15,890 for vaccination programs based on 2, 3, and 4 cohorts, respectively. With multicohort vaccination strategies, the reduction in the number of HPV-related events occurred earlier (range, 3.8-6.4 y) when compared with a single cohort. The analysis of the expected value of information showed that the results of the model were subject to limited uncertainty (cost per patient=&OV0556;12.6). CONCLUSIONS: This methodological approach is designed to incorporate the uncertainty associated with HPV vaccination. Modeling the cost-effectiveness of a multicohort vaccination program with Bayesian statistics confirmed the value for money of quadrivalent-based HPV vaccination. The expected value of information gave the most appropriate and feasible representation of the true value of this program.

Original languageEnglish
Pages (from-to)1076-1085
Number of pages10
JournalMedical Care
Volume50
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Cost-Benefit Analysis
Vaccination
Health
Uncertainty
Costs and Cost Analysis
Warts
Quality-Adjusted Life Years
Expert Testimony
Human Development
Statistical Models
Uterine Cervical Neoplasms

Keywords

  • Bayesian modeling
  • cost-effectiveness
  • HPV vaccination
  • multicohort strategy
  • uncertainty

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Favato, G., Baio, G., Capone, A., Marcellusi, A., Costa, S., Garganese, G., ... Mennini, F. S. (2012). Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST study. Medical Care, 50(12), 1076-1085. https://doi.org/10.1097/MLR.0b013e318269e06d

Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases : The BEST study. / Favato, Giampiero; Baio, Gianluca; Capone, Alessandro; Marcellusi, Andrea; Costa, Silvano; Garganese, Giorgia; Picardo, Mauro; Drummond, Mike; Jonsson, Bengt; Scambia, Giovanni; Zweifel, Peter; Mennini, Francesco S.

In: Medical Care, Vol. 50, No. 12, 12.2012, p. 1076-1085.

Research output: Contribution to journalArticle

Favato, G, Baio, G, Capone, A, Marcellusi, A, Costa, S, Garganese, G, Picardo, M, Drummond, M, Jonsson, B, Scambia, G, Zweifel, P & Mennini, FS 2012, 'Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST study', Medical Care, vol. 50, no. 12, pp. 1076-1085. https://doi.org/10.1097/MLR.0b013e318269e06d
Favato, Giampiero ; Baio, Gianluca ; Capone, Alessandro ; Marcellusi, Andrea ; Costa, Silvano ; Garganese, Giorgia ; Picardo, Mauro ; Drummond, Mike ; Jonsson, Bengt ; Scambia, Giovanni ; Zweifel, Peter ; Mennini, Francesco S. / Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases : The BEST study. In: Medical Care. 2012 ; Vol. 50, No. 12. pp. 1076-1085.
@article{41ca1df23b134041abc7566180e8c4fe,
title = "Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST study",
abstract = "BACKGROUND: The development of human papillomavirus (HPV)-related diseases is not understood perfectly and uncertainties associated with commonly utilized probabilistic models must be considered. The study assessed the cost-effectiveness of a quadrivalent-based multicohort HPV vaccination strategy within a Bayesian framework. METHODS: A full Bayesian multicohort Markov model was used, in which all unknown quantities were associated with suitable probability distributions reflecting the state of currently available knowledge. These distributions were informed by observed data or expert opinion. The model cycle lasted 1 year, whereas the follow-up time horizon was 90 years. Precancerous cervical lesions, cervical cancers, and anogenital warts were considered as outcomes. RESULTS: The base case scenario (2 cohorts of girls aged 12 and 15 y) and other multicohort vaccination strategies (additional cohorts aged 18 and 25 y) were cost-effective, with a discounted cost per quality-adjusted life-year gained that corresponded to &OV0556;12,013, &OV0556;13,232, and &OV0556;15,890 for vaccination programs based on 2, 3, and 4 cohorts, respectively. With multicohort vaccination strategies, the reduction in the number of HPV-related events occurred earlier (range, 3.8-6.4 y) when compared with a single cohort. The analysis of the expected value of information showed that the results of the model were subject to limited uncertainty (cost per patient=&OV0556;12.6). CONCLUSIONS: This methodological approach is designed to incorporate the uncertainty associated with HPV vaccination. Modeling the cost-effectiveness of a multicohort vaccination program with Bayesian statistics confirmed the value for money of quadrivalent-based HPV vaccination. The expected value of information gave the most appropriate and feasible representation of the true value of this program.",
keywords = "Bayesian modeling, cost-effectiveness, HPV vaccination, multicohort strategy, uncertainty",
author = "Giampiero Favato and Gianluca Baio and Alessandro Capone and Andrea Marcellusi and Silvano Costa and Giorgia Garganese and Mauro Picardo and Mike Drummond and Bengt Jonsson and Giovanni Scambia and Peter Zweifel and Mennini, {Francesco S.}",
year = "2012",
month = "12",
doi = "10.1097/MLR.0b013e318269e06d",
language = "English",
volume = "50",
pages = "1076--1085",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases

T2 - The BEST study

AU - Favato, Giampiero

AU - Baio, Gianluca

AU - Capone, Alessandro

AU - Marcellusi, Andrea

AU - Costa, Silvano

AU - Garganese, Giorgia

AU - Picardo, Mauro

AU - Drummond, Mike

AU - Jonsson, Bengt

AU - Scambia, Giovanni

AU - Zweifel, Peter

AU - Mennini, Francesco S.

PY - 2012/12

Y1 - 2012/12

N2 - BACKGROUND: The development of human papillomavirus (HPV)-related diseases is not understood perfectly and uncertainties associated with commonly utilized probabilistic models must be considered. The study assessed the cost-effectiveness of a quadrivalent-based multicohort HPV vaccination strategy within a Bayesian framework. METHODS: A full Bayesian multicohort Markov model was used, in which all unknown quantities were associated with suitable probability distributions reflecting the state of currently available knowledge. These distributions were informed by observed data or expert opinion. The model cycle lasted 1 year, whereas the follow-up time horizon was 90 years. Precancerous cervical lesions, cervical cancers, and anogenital warts were considered as outcomes. RESULTS: The base case scenario (2 cohorts of girls aged 12 and 15 y) and other multicohort vaccination strategies (additional cohorts aged 18 and 25 y) were cost-effective, with a discounted cost per quality-adjusted life-year gained that corresponded to &OV0556;12,013, &OV0556;13,232, and &OV0556;15,890 for vaccination programs based on 2, 3, and 4 cohorts, respectively. With multicohort vaccination strategies, the reduction in the number of HPV-related events occurred earlier (range, 3.8-6.4 y) when compared with a single cohort. The analysis of the expected value of information showed that the results of the model were subject to limited uncertainty (cost per patient=&OV0556;12.6). CONCLUSIONS: This methodological approach is designed to incorporate the uncertainty associated with HPV vaccination. Modeling the cost-effectiveness of a multicohort vaccination program with Bayesian statistics confirmed the value for money of quadrivalent-based HPV vaccination. The expected value of information gave the most appropriate and feasible representation of the true value of this program.

AB - BACKGROUND: The development of human papillomavirus (HPV)-related diseases is not understood perfectly and uncertainties associated with commonly utilized probabilistic models must be considered. The study assessed the cost-effectiveness of a quadrivalent-based multicohort HPV vaccination strategy within a Bayesian framework. METHODS: A full Bayesian multicohort Markov model was used, in which all unknown quantities were associated with suitable probability distributions reflecting the state of currently available knowledge. These distributions were informed by observed data or expert opinion. The model cycle lasted 1 year, whereas the follow-up time horizon was 90 years. Precancerous cervical lesions, cervical cancers, and anogenital warts were considered as outcomes. RESULTS: The base case scenario (2 cohorts of girls aged 12 and 15 y) and other multicohort vaccination strategies (additional cohorts aged 18 and 25 y) were cost-effective, with a discounted cost per quality-adjusted life-year gained that corresponded to &OV0556;12,013, &OV0556;13,232, and &OV0556;15,890 for vaccination programs based on 2, 3, and 4 cohorts, respectively. With multicohort vaccination strategies, the reduction in the number of HPV-related events occurred earlier (range, 3.8-6.4 y) when compared with a single cohort. The analysis of the expected value of information showed that the results of the model were subject to limited uncertainty (cost per patient=&OV0556;12.6). CONCLUSIONS: This methodological approach is designed to incorporate the uncertainty associated with HPV vaccination. Modeling the cost-effectiveness of a multicohort vaccination program with Bayesian statistics confirmed the value for money of quadrivalent-based HPV vaccination. The expected value of information gave the most appropriate and feasible representation of the true value of this program.

KW - Bayesian modeling

KW - cost-effectiveness

KW - HPV vaccination

KW - multicohort strategy

KW - uncertainty

UR - http://www.scopus.com/inward/record.url?scp=84870240117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870240117&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e318269e06d

DO - 10.1097/MLR.0b013e318269e06d

M3 - Article

C2 - 22922435

AN - SCOPUS:84870240117

VL - 50

SP - 1076

EP - 1085

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 12

ER -